Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meropenem + sulbactam + edetic acid
- Development stage
- Preclinical
- Lead developer
- Cosmas Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Parenteral
01
Overview
Meropenem + sulbactam + edetic acid is a fixed-dose combination antibiotic therapy developed by Cosmas Pharmaceuticals for the treatment of serious bacterial infections, particularly those caused by multi-drug resistant (MDR) Gram-negative pathogens. The combination consists of meropenem, a broad-spectrum carbapenem; sulbactam, a beta-lactamase inhibitor; and edetic acid (EDTA), a chelating agent. Meropenem works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Sulbactam protects meropenem from degradation by Class A and some Class C/D beta-lactamases. The inclusion of EDTA is intended to address resistance mediated by metallo-beta-lactamases (MBLs); EDTA chelates the divalent metal ions (such as zinc) that are essential cofactors for MBL activity, thereby restoring the susceptibility of MBL-producing bacteria to meropenem. This triple combination is administered parenterally.
- Other names
- meropenem + sulbactam + EDTAmeropenem + sulbactam sodium + ethylenediaminetetraacetic acidmeropenem + sulbactam + disodium edetate
02
Targets
Neuraminidaseβ-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on meropenem + sulbactam + edetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meropenem + sulbactam + edetic acid.